Sign In
Buy AKBA
$0.97
+0.0333 (+3.56%)
At Close: Jun 03, 2026
Raymond James & Associates Has $103,000 Stock Holdings in Akebia Therapeutics Inc (NASDAQ:AKBA)
08:15am, Monday, 13'th Apr 2020
Raymond James & Associates lessened its holdings in shares of Akebia Therapeutics Inc (NASDAQ:AKBA) by 23.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 16,309
Jane Street Group LLC Reduces Position in Akebia Therapeutics Inc (NASDAQ:AKBA)
08:46am, Sunday, 12'th Apr 2020
Jane Street Group LLC trimmed its stake in Akebia Therapeutics Inc (NASDAQ:AKBA) by 65.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission
Akebia Therapeutics (AKBA) Receives a Buy from H.C. Wainwright
05:41am, Sunday, 12'th Apr 2020
In a report issued on April 9, Ed Arce from H.C. Wainwright maintained a Buy rating on Akebia Therapeutics (AKBA
NEW YORK, April 10, 2020 -- Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Akebia Therapeutics,.
Akebia Therapeutics Inc (NASDAQ:AKBA) Shares Purchased by Goldman Sachs Group Inc.
10:02am, Friday, 10'th Apr 2020
Goldman Sachs Group Inc. raised its holdings in Akebia Therapeutics Inc (NASDAQ:AKBA) by 142.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commissi
INVESTOR ALERT: Fields Kupka & Shukurov LLP Is Investigating Akebia Therapeutics, Inc. ...
12:00am, Friday, 10'th Apr 2020Man Group plc Lowers Stock Position in Akebia Therapeutics Inc (NASDAQ:AKBA)
11:16am, Wednesday, 08'th Apr 2020
Man Group plc reduced its stake in shares of Akebia Therapeutics Inc (NASDAQ:AKBA) by 6.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Excha
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced the appoin
Humana Inc (NYSE: HUM) Q4 2019 Earnings Call Transcript | AlphaStreet
09:03pm, Monday, 06'th Apr 2020
Ladies and gentlemen, thank you for standing by and welcome to the Humana Fourth Quarter Earnings Call.
Victory Capital Management Inc. Has $190,000 Stock Position in Akebia Therapeutics Inc (NASDAQ:AKBA)
11:18am, Monday, 06'th Apr 2020
Victory Capital Management Inc. raised its position in Akebia Therapeutics Inc (NASDAQ:AKBA) by 50.9% in the 4th quarter, HoldingsChannel reports. The fund owned 30,111 shares of the biopharmaceutical
Advisor Group Inc. Increases Stake in Akebia Therapeutics Inc (NASDAQ:AKBA)
08:20am, Monday, 06'th Apr 2020
Advisor Group Inc. boosted its stake in Akebia Therapeutics Inc (NASDAQ:AKBA) by 52.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).
Akebia Therapeutics Inc (NASDAQ:AKBA) Receives Consensus Rating of "Buy" from Analysts
10:42am, Sunday, 05'th Apr 2020
Shares of Akebia Therapeutics Inc (NASDAQ:AKBA) have been given a consensus recommendation of “Buy” by the seven brokerages that are presently covering the company, MarketBeat.com reports. Two res
Credit Suisse AG Decreases Position in Akebia Therapeutics Inc (NASDAQ:AKBA)
09:12am, Sunday, 05'th Apr 2020
Credit Suisse AG cut its stake in Akebia Therapeutics Inc (NASDAQ:AKBA) by 17.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm
AQR Capital Management LLC Increases Holdings in Akebia Therapeutics Inc (NASDAQ:AKBA)
08:30am, Sunday, 05'th Apr 2020
AQR Capital Management LLC grew its holdings in shares of Akebia Therapeutics Inc (NASDAQ:AKBA) by 231.4% in the 4th quarter, according to the company in its most recent filing with the Securities and
Amalgamated Bank Purchases 1,703 Shares of Akebia Therapeutics Inc (NASDAQ:AKBA)
08:40am, Friday, 03'rd Apr 2020
Amalgamated Bank lifted its position in shares of Akebia Therapeutics Inc (NASDAQ:AKBA) by 9.7% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor
